Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Thyroid Gland Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 9 active trials
5 drugs · 3 active trials
10 drugs · 42 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 6 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab | Phase 2 | Phase 2 | 7 | 0 | 0 | 8 | 0 | — | — | Aug 17, 2015 |
| Pembrolizumab | Phase 2 | Phase 2 | 6 | 0 | 0 | 12 | 0 | — | — | Dec 18, 2015 |
| Cyclophosphamide | Phase 2 | Phase 2 | 4 | 2 | 0 | 6 | 0 | — | — | Mar 2, 2015 |
| Fludarabine | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Mar 2, 2015 |
| Ipilimumab | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | Jan 30, 2017 |
| Binimetinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Everolimus | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | 2004-12 |
| Cetuximab | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Oct 16, 2012 |
| Dabrafenib/Trametinib Regimen | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Dec 30, 2020 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | May 31, 2023 |
| Entrectinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Nov 19, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jul 27, 2017 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Sep 13, 2024 |
| Bevacizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2006-12 |
| Docetaxel | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2006-12 |
| Durvalumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 25, 2017 |
| Aldesleukin | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Mar 2, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2015-07 |
| Tipifarnib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | May 13, 2015 |
| Tislelizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Apr 12, 2021 |
| Toripalimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Oct 1, 2020 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Atezolizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 27, 2017 |
| Axitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 14, 2026 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Carboplatin/Paclitaxel Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2024 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Encorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 30, 2020 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| FOLFIRI Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 18, 2023 |
| Gemcitabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 18, 2023 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 14, 2024 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Panitumumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 18, 2023 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Sirolimus | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 27, 2017 |
| Tarlatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 8, 2025 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Cisplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-12 |
| Selumetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-12 |
| Alectinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 19, 2017 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.